SETD2 non genomic loss of function in advanced systemic mastocytosis is mediated by an Aurora kinase A/MDM2 axis and can be therapeutically targeted

SETD2 non genomic loss of function in advanced systemic mastocytosis is mediated by an Aurora kinase A/MDM2 axis and can be therapeutically targeted

Abstract Background The SETD2 tumor suppressor gene encodes a histone methyltransferase that safeguards transcription fidelity and genomic integrity via trimethylation of histone H3 lysine 36 (H3K36Me3). SETD2 loss of function has been observed in solid and hematologic malignancies. We have recently...

Full description

Bibliographic Details
Main Authors: Manuela Mancini, Cecilia Monaldi, Sara De Santis, Cristina Papayannidis, Michela Rondoni, Chiara Sartor, Samantha Bruno, Livio Pagano, Marianna Criscuolo, Roberta Zanotti, Massimiliano Bonifacio, Patrizia Tosi, Michel Arock, Peter Valent, Michele Cavo, Simona Soverini
Format: Article
Language:English
Published: BMC 2023-03-01
Series:Biomarker Research
Subjects:
SETD2
MDM2
Aurora kinase A
Polo-like kinase 1
Proteasome inhibitors
Online Access:https://doi.org/10.1186/s40364-023-00468-7

Internet

https://doi.org/10.1186/s40364-023-00468-7

Similar Items